0001974158-24-000009.txt : 20240215
0001974158-24-000009.hdr.sgml : 20240215
20240215170457
ACCESSION NUMBER: 0001974158-24-000009
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 24644718
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Heyman Richard A.
CENTRAL INDEX KEY: 0001584759
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: 5871 OBERLIN DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
144
1
primary_doc.xml
144
0001584759
XXXXXXXX
LIVE
0001672619
Enliven Therapeutics, Inc.
001-39247
6200 LOOKOUT ROAD
BOULDER
CO
80301
720-647-8519
Heyman Richard A.
Director
Common
Jefferies LLC
520 Madison Ave, 4th Fl
New York
NY
10022
3810
56578.50
41200000
02/15/2024
NASDAQ
Common
01/19/2022
Exercised Stock Options
Enliven Therapeutics, Inc.
N
3810
01/19/2022
N/A
N
Richard Heyman
6200 Lookout Road, 1st FL
Boulder
CO
80301
Enliven Therapeutics
12/19/2023
255
3315.00
Richard Heyman
6200 Lookout Road, 1st FL
Boulder
CO
80301
Enliven Therapeutics
12/20/2023
2110
27472.73
Richard Heyman
6200 Lookout Road, 1st FL
Boulder
CO
80301
Enliven Therapeutics
12/21/2023
7
91.00
Richard Heyman
6200 Lookout Road, 1st FL
Boulder
CO
80301
Enliven Therapeutics
12/22/2023
168
2184.00
Richard Heyman
6200 Lookout Road, 1st FL
Boulder
CO
80301
Enliven Therapeutics
01/30/2024
1270
20839.51
All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 07/17/2023, and all representations regarding material non-public information were made as of the adoption of the plan.
02/15/2024
07/17/2023
Richard Heyman